Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$282.12M+16.1%$269.78M+16.0%$256.27M+16.8%$250.89M+21.9%$242.98M+27.6%
$79.92M+75.7%$63.58M+46.9%$51.34M+24.9%$48.77M+25.9%$45.49M+23.4%
$362.04M+25.5%$333.36M+20.8%$307.6M+18.1%$299.66M+22.5%$288.47M+26.9%
-$362.04M-25.5%-$333.36M-20.8%-$307.6M-18.1%-$299.66M-22.5%-$288.47M-26.9%
$4.28M$3.06M
$19.35M+13.9%$14.69M-18.8%$13.07M-27.8%$13.96M-20.3%$16.98M+14.2%
$13.23M-27.0%$15.59M-11.2%$18.97M+25.4%
-$7.18M-$5.39M-$3.59M-$1.8M
-$354.3M-31.5%-$328.94M-28.6%-$294.37M-21.5%-$284.08M-25.1%-$269.5M-27.0%
-$2.17-10.2%-$2.16-11.3%-$2.05-28.9%-$2.07-21.1%-$1.97-5.3%
-$2.17-10.2%-$2.16-11.3%-$2.05-28.9%-$2.07-21.1%-$1.97-5.3%
543.1M+27.3%494.2M+21.1%469.2M+22.2%441.8M+22.8%426.6M+27.2%
543.1M+27.3%494.2M+21.1%469.2M+22.2%441.8M+22.8%426.6M+27.2%
-$354.88M-31.8%-$329.03M-28.7%-$295.06M-22.3%-$283.87M-25.0%-$269.29M-26.9%
$0+100%
-$155K-108%-$20K-101%$1.93M+4,295%$1.94M+4,407%$1.99M+645%
-$362.04M-25.5%-$333.36M-20.8%-$307.6M-18.1%-$299.66M-22.5%-$288.47M-26.9%
-$359.47M-25.7%-$330.79M-20.9%-$305.06M-18.2%-$297.14M-22.7%-$285.99M-27.1%
-$359.47M-25.7%-$330.79M-20.9%-$305.06M-18.2%-$297.14M-22.7%-$285.99M-27.1%
-$362.04M-25.5%-$333.36M-20.8%-$307.6M-18.1%-$299.66M-22.5%-$288.47M-26.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Cogent Biosciences, Inc.'s revenue?
Cogent Biosciences, Inc. (COGT) generated $7.9M in revenue over the trailing twelve months, down 65.0% year over year.
Is Cogent Biosciences, Inc. profitable?
Cogent Biosciences, Inc. is not currently profitable: it reported a net loss of $354.3M over the trailing twelve months, a -950.4% net margin.
What is Cogent Biosciences, Inc.'s earnings per share?
Cogent Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-2.17.
Where does Cogent Biosciences, Inc.'s income statement data come from?
Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.